Novo Nordisk's decision has been criticized by some patients with Type 1 diabetes who prefer Levemir over other long-acting "basal" insulins such as Sanofi's Lantus and Novo Nordisk's Tresiba.

The top of executive of Novo Nordisk told a Senate panel Tuesday it was a "difficult choice" to discontinue the long-acting insulin Levemir but he had to do so because of market forces. The Danish ...

Novo Nordisk's decision has been criticized by some patients with Type 1 diabetes who prefer Levemir over other long-acting "basal" insulins such as Sanofi's Lantus and Novo Nordisk's Tresiba.

Patients push back against Novo Nordisk move to scrap an insulin product The Danish drugmaker said in November it would halt U.S. sales of Levemir by the end of 2024.

Novo Nordisk's decision to stop selling its long-acting insulin Levemir in the ... Jaime Losinki's teenaged son was diagnosed with type 1 diabetes seven years ago and prescribed Sanofi's Lantus.

Novo Nordisk's decision to stop selling its long-acting insulin Levemir in the United States has left some diabetes patients struggling to switch treatments, patients and doctors in a dozen U.S.

Novo Nordisk's decision to stop selling its long-acting insulin Levemir in the United States has left some diabetes patients struggling to switch treatments, patients and doctors in a dozen U.S ...

"Levemir’s action profile makes it perfect for patients who need to make rapid and continual changes," she went on. "An insulin such as Lantus or Tresiba, which the industry tells us to ‘just ...

There are several other basal insulin options available besides Levemir, she added, including Eli Lilly's Basaglar and Rezvoglar, as well as Sanofi's long-acting insulin Lantus or its Viatris-made ...

Three U.S. Senators say they are "alarmed" Novo Nordisk discontinued U.S. sales of a popular insulin brand and are demanding answers from the pharmaceutical giant they say left patients without an ...

Three U.S. Senators say they are "alarmed" Novo Nordisk discontinued U.S. sales of a popular insulin brand and are demanding answers from the pharmaceutical giant they say left patients without an ...

After she was diagnosed at age 48 with Type 1 diabetes, Stacey Silverman muddled through her days with high blood sugar, fatigue and splitting headaches. Taking a long-acting form of insulin called ...